CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On February 8, 2018, Chembio Diagnostics, Inc. issued a press release announcing a new tender win and certain preliminary unaudited financial results for the full year ended December 31, 2017. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Exhibits.

99.1 Press release dated February 8, 2018.

CHEMBIO DIAGNOSTICS, INC. Exhibit
EX-99.1 2 tv485263_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1       Chembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial Results   MEDFORD,…
To view the full exhibit click here

About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.